Immatics IMA203 PRAME Cell Therapy Data Presented at 2025 ASCO Annual Meeting Continues to Show Strong Anti-tumor Activity and Durability in Patients with Metastatic Melanoma
• Extended Phase 1b trial follow-up on IMA203 PRAME cell therapy in 33 heavily pretreated patients with metastatic melanoma demonstrates favorable tolerability and promising clinical activity with ongoing deep and durable objective responses up to >2.5 years • IMA203 PRAME cell therapy one-time ...
Harbinger Health Showcases Multi-Cancer Early Detection Performance in High-Risk Populations at ASCO 2025
Harbinger Health Showcases Multi-Cancer Early Detection Performance in High-Risk Populations at ...
Xilio Therapeutics Announces Updated Phase 2 Data for Vilastobart, a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer
26% preliminary objective response rate observed in heavily pre-treated patients with metastatic microsatellite stable colorectal cancer ( MSS CRC ) without liver metastases
Maryland Student Wins NFTE Capital Youth Entrepreneurship Challenge
Washington, DC, May 31, 2025 ( GLOBE NEWSWIRE ) -- Global entrepreneurship education nonprofit Network for Teaching Entrepreneurship ( NFTE ) has named four local student businesses as the winners of its annual Capital Regional Youth Entrepreneurship Challenge.
Arvinas and Pfizer's Vepdegestrant Significantly Improves Progression-Free Survival for Patients with ESR1-Mutant, ER+/HER2- Advanced Breast Cancer
• Pivotal Phase 3 VERITAC-2 clinical trial results presented at ASCO demonstrate 2.9-month improvement in median progression-free survival when compared to fulvestrant in second line-plus patients with an estrogen receptor 1 mutation • Vepdegestrant was generally well tolerated, with few ...
Arvinas and Pfizer's Vepdegestrant Significantly Improves Progression-Free Survival for Patients with ESR1-Mutant, ER+/HER2- Advanced Breast Cancer - Arvinas ( NASDAQ:ARVN ) , Pfizer ( NYSE:PFE )
Pivotal Phase 3 VERITAC-2 clinical trial results presented at ASCO demonstrate 2.9-month improvement in median progression-free survival when compared to fulvestrant in second line-plus patients with an estrogen receptor 1 mutation
Libtayo® ( cemiplimab ) Phase 3 Data in the Adjuvant Treatment of Post-Surgical High-Risk Cutaneous Squamous Cell Carcinoma ( CSCC ) Have Potential to Be Practice-Changing
Libtayo demonstrated a 68% reduction in the risk of disease recurrence or death, the primary endpoint of the trial ...
Libtayo® ( cemiplimab ) Phase 3 Data in the Adjuvant Treatment of Post-Surgical High-Risk Cutaneous Squamous Cell Carcinoma ( CSCC ) Have Potential to Be Practice-Changing - Regeneron Pharmaceuticals ( NASDAQ:REGN )
Detailed results presented in an oral session at the 2025 American Society of Clinical Oncology Annual Meeting and simultaneously published in the New England Journal of Medicine TARRYTOWN, N.Y., May 31, 2025 ( GLOBE NEWSWIRE ) -- Regeneron Pharmaceuticals, Inc.
Libtayo® ( cemiplimab ) Phase 3 Data in the Adjuvant Treatment of Post-Surgical High-Risk Cutaneous Squamous Cell Carcinoma ( CSCC ) Have Potential to Be Practice-Changing
Libtayo® (cemiplimab) Phase 3 Data in the Adjuvant Treatment of Post-Surgical High-Risk Cutaneous Squamous Cell Carcinoma (CSCC) Have Potential to Be ...